Glenmark Pharma - Public Comps and Valuation Multiples

Glenmark Pharma Overview

About Glenmark Pharma

Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities. It has a business presence in different therapeutic areas such as dermatology, respiratory, oncology, diabetes, cardiovascular, and oral contraceptives among others. Geographically, it derives key revenue from India and the rest from North America, Latin America, Europe and the Rest of the world.

Founded

1977

HQ

Employees

13.5K+

Website

glenmarkpharma.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $1.6B

LTM EBITDA $332M

EV

$6.3B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Glenmark Pharma Financials

As of September 2025, Glenmark Pharma reported last 12-month revenue of $1.6B and EBITDA of $332M.

In the same period, Glenmark Pharma generated $1.1B in LTM gross profit and $183M in net income.

See Glenmark Pharma valuation multiples based on analyst estimates

Glenmark Pharma P&L

In the most recent fiscal year, Glenmark Pharma reported revenue of $1.5B and EBITDA of $236M.

Glenmark Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Glenmark Pharma valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$1.6B	XXX	$1.5B	XXX	XXX	XXX
Gross Profit	$1.1B	XXX	$945M	XXX	XXX	XXX
Gross Margin	69%	XXX	64%	XXX	XXX	XXX
EBITDA	$332M	XXX	$236M	XXX	XXX	XXX
EBITDA Margin	21%	XXX	16%	XXX	XXX	XXX
EBIT	$280M	XXX	$210M	XXX	XXX	XXX
EBIT Margin	17%	XXX	14%	XXX	XXX	XXX
Net Profit	$183M	XXX	$118M	XXX	XXX	XXX
Net Margin	11%	XXX	8%	XXX	XXX	XXX
Net Debt	XXX	XXX	$58.4M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Glenmark Pharma including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $1.6B. EBITDA for the last twelve months was $332M. In the most recent fiscal year, Glenmark Pharma achieved $1.5B in revenue and $236M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$1.6B	Analyst estimates available to subscribers	$1.5B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$1.1B	Analyst estimates available to subscribers	$945M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	68.7% gross margin	Analyst estimates available to subscribers	63.8% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$332M	Analyst estimates available to subscribers	$236M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	20.6% EBITDA margin	Analyst estimates available to subscribers	15.9% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$280M	Analyst estimates available to subscribers	$210M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	17.4% EBIT margin	Analyst estimates available to subscribers	14.2% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$183M	Analyst estimates available to subscribers	$118M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	11.3% net profit margin	Analyst estimates available to subscribers	8.0% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$58.4M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Glenmark Pharma

This financial data table provides comprehensive performance metrics for Glenmark Pharma, a company based in India. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Glenmark Pharma generated $1.6B in revenue over the last twelve months.
The company achieved $332M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $1.1B.
Net income over the last twelve months reached $183M.

Fiscal Year Performance

In the most recent fiscal year, Glenmark Pharma reported $1.5B in total revenue.
Fiscal year EBITDA was $236M.
The company maintained a gross profit margin of 63.8% in the most recent fiscal year.
EBITDA margin for the fiscal year was 15.9%.
Net profit margin reached 8.0% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Glenmark Pharma. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Glenmark Pharma Stock Performance

Glenmark Pharma has current market cap of INR 553B (or $6.2B), and EV of INR 561B (or $6.3B).

Market Cap Evolution

Glenmark Pharma Stock Data

As of October 2, 2025, Glenmark Pharma's stock price is INR 1959 (or $22).

See Glenmark Pharma trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$6.3B	$6.2B	XXX	XXX	XXX	XXX	$0.63

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Glenmark Pharma Valuation Multiples

Glenmark Pharma's trades at 4.4x EV/Revenue multiple, and 30.1x EV/EBITDA.

See valuation multiples for Glenmark Pharma and 15K+ public comps

Glenmark Pharma Financial Valuation Multiples

As of October 2, 2025, Glenmark Pharma has market cap of $6.2B and EV of $6.3B.

Equity research analysts estimate Glenmark Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Glenmark Pharma has a P/E ratio of 34.0x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$6.2B	XXX	$6.2B	XXX	XXX	XXX
EV (current)	$6.3B	XXX	$6.3B	XXX	XXX	XXX
EV/Revenue	3.9x	XXX	4.4x	XXX	XXX	XXX
EV/EBITDA	19.0x	XXX	30.1x	XXX	XXX	XXX
EV/EBIT	22.5x	XXX	36.0x	XXX	XXX	XXX
EV/Gross Profit	5.7x	XXX	n/a	XXX	XXX	XXX
P/E	34.0x	XXX	134.8x	XXX	XXX	XXX
EV/FCF	56.1x	XXX	-38.0x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Glenmark Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Glenmark Pharma Margins & Growth Rates

Glenmark Pharma's last 12 month revenue growth is 12%

Glenmark Pharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Glenmark Pharma's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Glenmark Pharma's rule of X is 50% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Glenmark Pharma and other 15K+ public comps

Glenmark Pharma Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	12%	XXX	13%	XXX	XXX	XXX
EBITDA Margin	21%	XXX	15%	XXX	XXX	XXX
EBITDA Growth	22%	XXX	39%	XXX	XXX	XXX
Rule of 40	26%	XXX	26%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	50%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	10%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	50%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial